Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Status:
Terminated
Trial end date:
2016-09-15
Target enrollment:
Participant gender:
Summary
To identify a dose of dacomitinib in combination with pemetrexed that is safe and tolerated
as determined by the incidence of DLTs (dose limiting toxicities).